Ignite Creation Date:
2024-05-06 @ 1:30 PM
Last Modification Date:
2024-10-26 @ 1:15 PM
Study NCT ID:
NCT04042558
Status:
RECRUITING
Last Update Posted:
2023-08-01
First Post:
2019-07-29
Brief Title:
A Study Evaluating Platinum-Pemetrexed-Atezolizumab -Bevacizumab for Patients With Stage IIIBIV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
Sponsor:
Centre Francois Baclesse
Organization:
Centre Francois Baclesse
Study Overview
Official Title:
A Multicentre Phase II Open-label Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab - Bevacizumab for Patients With Stage IIIBIV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GFPC 06-2018
Brief Summary:
The objective of this study is to assess the efficacy of the combination of Platinum carboplatin or cisplatin Pemetrexed Atezolizumab- Bevacizumab if eligible in stage IIIBIV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies
Detailed Description:
In patients with an EGFR mutation several phase III studies comparing EGFR tyrosine kinase inhibitors TKIs with chemotherapy have shown a benefit of TKI over chemotherapy with no demonstrated benefit on overall survival After a first line of treatment with a TKI most patients progress and are eligible according to the mechanism of progression to a TKI of 3rd generation in case of T790M resistance or chemotherapy In patients with ALK translocation crizotinib has been shown to be beneficial in first line compared to a platinum doubletDespite these major advances most patients are progressing after targeted treatments and chemotherapy and are facing the problem of anti-PD1 PDL1 treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None